Navigation Links
Repligen to Present at the Rodman & Renshaw 10th Annual Healthcare Conference Monday, November 10th, 4:55 p.m. EST
Date:11/3/2008

n, management's strategy, plans and objectives for future operations, plans and objectives for product development, plans and objectives for present and future clinical trials and results of such trials, plans and objectives for regulatory approval, litigation, intellectual property, product development, manufacturing plans and performance such as the anticipated growth in the monoclonal antibody market and our other target markets and projected growth in product sales, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with: the success of current and future collaborative relationships, the market acceptance of our products, our ability to compete with larger, better financed pharmaceutical and biotechnology companies, new approaches to the treatment of our targeted diseases, our expectation of incurring continued losses, our uncertainty of product revenues and profits, our ability to generate future revenues, our ability to raise additional capital to continue our drug development programs, the success of our clinical trials, our ability to develop and commercialize products, our ability to obtain required regulatory approvals, our compliance with all Food and Drug Administration regulations, our ability to obtain, maintain and protect intellectual property rights for our products, the risk of litigation regarding our intellectual property rights, our limited sales and manufacturing capabilities, our dependence on third-party manufacturers and value added resellers, our ability to hire and retain skilled personnel, our volatile stock price, and other risks detailed in Repligen's filings with the Securities and Exchange Commission. Repligen assumes no obligation to update any forward-looking information contained in this press release or with respect to the announcements d
'/>"/>
SOURCE Repligen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Repligen to Present at the 2008 UBS Global Life Sciences Conference Wednesday, September 24th, 1:00 p.m. EDT
2. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
3. Repligen Receives Research Grants to Support Friedreichs Ataxia Development Program
4. Repligen Announces Conference Call of First Quarter Fiscal Year 2009 Results
5. Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
6. Repligen Announces Settlement with Bristol-Myers Squibb in Orencia(R) Lawsuit
7. Repligen Announces Conference Call of Third Quarter Fiscal Year 2008 Results
8. RainDance Technologies to Present Sequence Enrichment Using Droplet-Based Microfluidics Workshop at ASHG 2008
9. SCOLR Pharma, Inc. to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
10. Nile Therapeutics to Present at Two Upcoming Investor Conferences
11. Arno Therapeutics to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... The Microcompetition with Foreign DNA theory explains how latent ... viruses is the Epstein Barr Virus (EBV), and one of ... a chronic inflammatory disease that destroys the body’s joints. As ... have high concentrations of EBV DNA in their bodies (1). ...
(Date:1/15/2014)... TAIPEI , Jan. 15, 2014 TaiGen Biotechnology ... an exclusive agreement with R-Pharm, a leading Russian pharmaceutical ... in the Russian Federation , ... Commonwealth Independent States (CIS). Nemonoxacin is a novel antibiotic for ...
(Date:1/14/2014)... Calif. , Jan. 14, 2014 As pet owners drew ... doubt many of them wrote: "Take better care of my furry ... even designer clothes and top-brand carrying cases to take the little ... parents might also feel compelled to buy some pricey toys at ...
(Date:1/14/2014)... Toronto, Canada (PRWEB) January 14, 2014 ... and its motives and methods in product development and ... of the industry. This mistrust, fueled by concerns about ... further fed by reports of spectacular fines to the ...
Breaking Biology Technology:Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3
... life sciences industry faces a host of policy ... and nationally, SAN FRANCISCO, Jan. 10 ... providing a broad overview of,the productivity of Northern ... science research cluster in the world. To ensure,continued ...
... France, January 10 Transgene,(Euronext Paris: FR0005175080) announces ... its therapeutic vaccine TG4010,(MVA-MUC1-IL2) as an adjunct to ... lung cancer (NSCLC)., This on-going trial is ... assess the efficacy of TG4010 in combination with ...
... BIRMINGHAM, Alabama,Jan. 10 CANTOX HEALTH SCIENCES INC. ... regulatory consulting firm with,specialized expertise in the areas ... Agriculture, Biotech & Consumer Products announces,the launch of ... their,Pharmaceutical & Healthcare Division., For the past ...
Cached Biology Technology:Bioscience Group Warns Policymakers Against Complacency 2Bioscience Group Warns Policymakers Against Complacency 3Transgene's Therapeutic Vaccine TG4010 Shows Promising Preliminary Phase IIb Data in Advanced Non-Small Cell Lung Cancer 2Transgene's Therapeutic Vaccine TG4010 Shows Promising Preliminary Phase IIb Data in Advanced Non-Small Cell Lung Cancer 3Cantox Announces the Launch of Ashuren Health Sciences Pharmaceutical Division 2
(Date:4/17/2014)... researchers have detected new early-warning signs of the potential ... have far-reaching implications for the diagnosis and treatment of ... million Americans. , "We had not expected to see ... stages," said Ann Elsner, professor and associate dean in ... the study. "We set out to study the early ...
(Date:4/17/2014)... full of wild animals and plant life, but there,s ... churning away in the soil, decomposing organic matter and ... role these fungi play in ecological systems, their identities ... scientists has generated a genetic map of more than ... was published this week in the Proceedings of ...
(Date:4/17/2014)... Modern View of Domestication," a special feature of ... Sciences ( PNAS ) published April 29, raises ... our deep history that most of us take for ... people in many spots around the globe shifted from ... livestock and plants. , It seems so straightforward and ...
Breaking Biology News(10 mins):New technique detects microscopic diabetes-related eye damage 2New technique detects microscopic diabetes-related eye damage 3Stanford biologists help solve fungal mysteries 2Stanford biologists help solve fungal mysteries 3Genetic study tackles mystery of slow plant domestications 2Genetic study tackles mystery of slow plant domestications 3Genetic study tackles mystery of slow plant domestications 4
... research at the Hebrew University of Jerusalem sheds light ... themselves indefinitely and to differentiate into all types of ... challenge in modern biology, could expedite the use of ... If scientists can replicate the mechanisms that make pluripotency ...
... Calif. As spatial planning is used increasingly to manage ... the best ways to use and refine the various spatial ... of the most common methods, which limit or entirely curtail ... in the early edition of the Proceedings of the ...
... used tiny, artificial fiber scaffolds thousands of times smaller than ... into cartilage, the shock-absorbing lining of elbows and knees that ... 4 in the Proceedings of the National Academy of ... both laboratory and animal models. While the findings are still ...
Cached Biology News:Researchers identify mechanisms that allow embryonic stem cells to become any cell in the human body 2Refining the tool kit for sustainable fisheries 2Refining the tool kit for sustainable fisheries 3Nanoscale scaffolds and stem cells show promise in cartilage repair 2Nanoscale scaffolds and stem cells show promise in cartilage repair 3
Mouse polyclonal antibody to PRDM2 - PR domain containing 2, with ZNF domain...
Intestinal Epithelium Differentiation Environment...
... Anti-phospho-Hck [pTyr 209/ pSer 211 ] ... solution in Dulbecco's phosphate buffered saline (without Mg ... with 1.0 mg/ml BSA (IgG and protease free) ... derived from the region of mouse Hck that ...
... provides a familiar interface for data ... warehousing. The transition from paper to ... LABTrack contains an integrated LIMS, ... rules mechanism. These functions allow LABTrack ...
Biology Products: